 |
|
|
| |
High SVR Rates Despite Multiple Negative Predictors in Genotype 1 Patients Receiving Ombitasvir/Paritaprevir/r, Dasabuvir With or Without Ribavirin For 12 and 24 Weeks: Integrated Analysis of Six Phase 3 Trials
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Nancy Reau1, Michael W Fried2, Heiner Wedemeyer3, Curtis Cooper4, Moises Diago5, Antonio Craxi6, Simone Strasser7, Jean-Francois DuFour8, Wangang Xie9, Lois Larsen9, Emily O Dumas9, David Bernstein10
1University of Chicago Medical Center, Chicago, Illinois, United States; 2University of North Carolina, Chapel Hill, North Carolina, United States; 3Medizinische Hochschule Hannover, Hannover, Germany; 4University of Ott awa, Ott awa, Ontario, Canada; 5Hospital Quiron de Valencia, Valencia, Spain; 6AOU Policlinico "P. Giaccone" Dip. Di Gastroenterologia ed Epatologia DBMIS, Palermo, Italy; 7AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; 8University Clinic for Visceral Surgery and Medicine, Bern, Switzerland; 9AbbVie Inc., North Chicago, Illinois, United States; 10North Shore University Hospital, Manhasset, New York, United States
|
| |
|
|
|
|
|
